Myxofibrosarcoma

16 registered clinical trials studyying Myxofibrosarcoma — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarc NCT07173972	Oslo University Hospital	Phase 2
Not Yet Recruiting	Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk T NCT06526897	ECOG-ACRIN Cancer Research Group	N/A
Recruiting	NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation The NCT06239272	St. Jude Children's Research Hospital	Phase 1 / Phase 2
Withdrawn	Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma NCT05116800	Brown University	Phase 2
Withdrawn	A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas NCT04906876	Brown University	Phase 2
Active Not Recruiting	ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or NCT04480502	Tracon Pharmaceuticals Inc.	Phase 2
Active Not Recruiting	Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma NCT04420975	Jonsson Comprehensive Cancer Center	Phase 1
Recruiting	A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma NCT04332874	Memorial Sloan Kettering Cancer Center	Phase 2
Completed	Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas NCT04242238	Memorial Sloan Kettering Cancer Center	Phase 1
Completed	CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma NCT03425279	BioAtla, Inc.	Phase 1 / Phase 2
Completed	Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot B NCT03009201	OHSU Knight Cancer Institute	Phase 1
Unknown	Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Ex NCT03651375	Maria Sklodowska-Curie National Research Institute of Oncology	Phase 2
Completed	Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma NCT02584309	Washington University School of Medicine	Phase 2
Terminated	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma NCT02601209	National Cancer Institute (NCI)	Phase 1 / Phase 2
Active Not Recruiting	Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients Wi NCT02180867	National Cancer Institute (NCI)	Phase 2 / Phase 3
Completed	Alisertib in Treating Patients With Advanced or Metastatic Sarcoma NCT01653028	National Cancer Institute (NCI)	Phase 2